Induced Pluripotent Stem Cell (iPS Cell): 2018-2022 …
Posted: August 4, 2018 at 3:41 pm
Dublin, Aug. 02, 2018 (GLOBE NEWSWIRE) -- The "Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2018-19" report has been added to ResearchAndMarkets.com's offering.
Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSCs). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods. Research and experimentation using mouse cells by Shinya Yamanaka's lab at Kyoto University in Japan was the first instance in which there was a successful generation of iPSCs.
In 2007, a series of follow-up experiments were done at Kyoto University in which human adult cells were transformed into iPSCs. Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.
Since the discovery of iPSCs a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. While it is clear that iPSCs represent a lucrative product market, methods for commercializing this cell type are still being explored, as clinical studies investigating iPSCs continue to increase in number.
iPS Cell Therapies
2013 was a landmark year in Japan because it saw the first cellular therapy involving the transplant of iPS cells into humans initiated at the RIKEN Center in Kobe, Japan. Led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB). Dr. Takahashi was investigating the safety of iPSC-derived cell sheets in patients with wet-type age-related macular degeneration.
Although the study was suspended in 2015 due to safety concerns, in June 2016 RIKEN Institute announced that it would resume the clinical study using allogeneic rather than autologous iPSC-derived cells, because of the cost and time efficiencies.
In a world-first, Cynata Therapeutics received approval in September 2016 to launch the world's first formal clinical trial of an allogeneic iPSC-derived cell product, called CYP-001. The study involves centers in the UK and Australia. In this trial, Cynata is testing an iPS cell-derived mesenchymal stem cell (MSC) product for the treatment of GvHD.
On 16 May 2018, Nature News then reported that Japan's health ministry gave doctors at Osaka University permission to take sheets of tissue derived from iPS cells and graft them onto diseased human hearts. The team of Japanese doctors, led by cardiac surgeon Yoshiki Sawa at Osaka University, will use iPS cells to create a sheet of 100 million heart-muscle cells. From preclinical studies in pigs, the medical team determined that thin sheets of cell grafts can improve heart function, likely through paracrine signaling.
Kyoto University Hospital in Kobe, Japan also stated it would be opening an iPSC therapy center in 2019, for purposes of conducting clinical studies on iPS cell therapies. Officials for Kyoto Hospital said it will open a 30-bed ward to test the efficacy and safety of the therapies on volunteer patients, with the hospital aiming to initiate construction at the site in February of 2016 and complete construction by September 2019.
iPS Cell Market Competitors
In 2009 ReproCELL, a company established as a venture company originating from the University of Tokyo and Kyoto University was the first to make iPSC products commercially available with the launch of its human iPSC-derived cardiomyocytes, which it called ReproCario.
Cellular Dynamics International, a Fujifilm company, is another major market player in the iPSC sector. Similar to ReproCELL, CDI established its control of the iPSC industry after being founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 derived iPSC lines from human somatic cells for the first time ever (the feat was accomplished simultaneously by Dr. Shinya Yamanaka's lab in Japan).
A European leader within the iPSC market is Ncardia, formed through the merger of Axiogenesis and Pluriomics. Founded in 2001 and headquartered in Cologne, Germany, Axiogenesis initially focused on generating mouse embryonic stem cell-derived cells and assays. After Yamanaka's groundbreaking iPSC technology became available, Axiogenesis was the first European company to license and adopt Yamanaka's iPSC technology in 2010.
Ncardia's focus lies on preclinical drug discovery and drug safety through the development of functional assays using human neuronal and cardiac cells, although it is expanding into new areas. Its flagship offering is its Cor.4U human cardiomyocyte product family, including cardiac fibroblasts.
In summary, market leaders have emerged in all areas of iPSC development, including:
iPS Cell Commercialization
Key Findings
Key Topics Covered
1. SCOPE AND METHODOLOGY
2. EXECUTIVE SUMMARY
3. BACKGROUND - iPSC RESEARCH
4. MARKET ANALYSIS BY PRODUCT CATEGORY
5. MARKET ANALYSIS BY APPLICATION
6. MARKET ANALYSIS BY GEOGRAPHY
7. PATENTS
8. COMPANIES
9. COMPANY PROFILES
10. CONCLUSIONS
For more information about this report visit https://www.researchandmarkets.com/research/njhzjc/induced?w=12
View post:
Induced Pluripotent Stem Cell (iPS Cell): 2018-2022 ...
- Stem Cell Therapy For Knees | What You Need To Know ... - February 12th, 2019
- The Cost Of Stem Cell Therapy And Why It's So Expensive ... - February 10th, 2019
- Somatic cell nuclear transfer - Wikipedia - February 8th, 2019
- Parkinson's Glossary: The Michael J. Fox Foundation ... - February 8th, 2019
- Cellular Therapies Section Subsections - AABB - February 8th, 2019
- Stem Cell Therapy in Thailand - Beike Biotech - Hospitals - February 5th, 2019
- Stem Cell Therapy for ALS Patients - February 3rd, 2019
- Stem Cell Therapy Has a Lot to OfferIt Just May Take Some ... - January 24th, 2019
- FUJIFILM Cellular Dynamics to Establish New Facility for ... - January 9th, 2019
- FUJIFILM Cellular Dynamics to Establish New Production ... - January 9th, 2019
- Cellular Therapy - fujifilmcdi.com - October 19th, 2018
- Kotton Lab - Boston University Medical Campus | Boston ... - October 2nd, 2018
- Market Players Developing iPS Cell Therapies - BioInformant - September 17th, 2018
- IPS and G-CON Launch iCON Cell Therapy Facility Platform - September 10th, 2018
- CTERP International Conference - 2018: About - July 11th, 2018
- Stem Cell Treatment/Therapy COST in India| DheerajBojwani.Com - June 25th, 2018
- iPS Cell Therapy: Is Japan the Market Leader? - June 18th, 2018
- Cell Therapy Companies - BioInformant - June 16th, 2018
- iPS Cell Therapy - Parent Project Muscular Dystrophy - June 15th, 2018
- New Jersey Stem Cell Therapy - Stem Cell Center Of NJ - April 15th, 2018
- Stem Cell Therapy for Duchenne Muscular Dystrophy ... - March 16th, 2018
- Lung Institute | Stem Cell Research Study for Lung Disease - March 8th, 2018
- Stem Cell Center Of NJ - New Jersey Stem Cell Therapy - January 26th, 2018
- Pluripotent Stem CellBased Therapy for Heart Disease ... - January 26th, 2018
- Stem Cell Therapy & Treatment - Diseases and Conditions - January 1st, 2018
- Stem Cell-Based Therapy for Cartilage Regeneration and ... - November 22nd, 2017
- Cell Replacement Therapy For Parkinsons Disease And The ... - November 10th, 2017
- The Promise of Induced Pluripotent Stem Cells (iPSCs ... - September 7th, 2017
- Center for Embryonic Cell and Gene Therapy | Center for ... - September 3rd, 2017
- Monkeys With Parkinson's Disease Successfully Treated With Human Stem Cell Transplants - Technology Networks - September 3rd, 2017
- iPS Cell-based Neuron Therapy Benefits Monkeys With Parkinson's - ReliaWire - September 3rd, 2017
- This Week In Neuroscience News 8/31/17 - ReliaWire - September 3rd, 2017
- Xeno-free cell culture medium for regenerative medicine research - Scientist Live - September 2nd, 2017
- Xeno-free Cell Culture Medium for Regenerative Medicine Research - Technology Networks - September 2nd, 2017
- Reprogrammed cells relieve Parkinson's symptoms in trials - Nature.com - September 1st, 2017
- Wasteful spending on medical public works - The Japan Times - August 28th, 2017
- For Immune System Stem Cell Studies, Mice Aren't Enough - Science 2.0 - August 26th, 2017
- An Experts Perspective on Accelerated Pathways for Cell ... - August 20th, 2017
- Daiichi Sankyo hearts Cuorips - Global University Venturing - August 10th, 2017
- Daiichi Sankyo invests in Osaka University spin-off - The Pharma Letter (registration) - August 9th, 2017
- Affimed Therapeutics' (AFMD) CEO Adi Hoess on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 4th, 2017
- Cellular Therapy - The World Leader in Stem Cell Technology - July 31st, 2017
- Ventolin proair - Rsv breathing treatments albuterol - Van Wert independent - July 11th, 2017
- Proventil hfa ventolin hfa - Proventil inhaler dosage for adults - Longboat Key News - July 6th, 2017
- The Gilmer Mirror - Hurray for Gurdon and Yamanaka Nobel Prize ... - Gilmer Mirror - July 6th, 2017
- Stem cells: JP2MRI, CET discover safer, more ethical biotechnology - Sioux City Catholic Globe - June 30th, 2017
- Hurray for Gurdon and Yamanaka, Nobel Prize Winners for Pro-life Medicine - Gilmer Mirror - June 29th, 2017
- Novel Findings Obtained with the PURE EP System to be Presented at American Heart Association's BCVS Scientific ... - Cardiovascular Business - June 26th, 2017
- Intranasal ipratropium in the treatment of vasomotor rhinitis - Queens Tribune - June 26th, 2017
- Cipro false positive drug test - Queens Tribune - June 25th, 2017
- Stem cells: the future of medicine - Medical Xpress - June 23rd, 2017
- Probing Psychoses - Harvard Magazine - June 17th, 2017
- 3D Artificial Skin Used To Treat Spina Bifida In Rats - Asian Scientist Magazine - June 15th, 2017
- Transplants using iPS cells put Riken specialist at forefront of regenerative medicine research - The Japan Times - June 14th, 2017
- What Are Stem Cells - Checkbiotech.org (press release) - June 4th, 2017
- Trends in Drug Discovery Outsourcing: A Perspective - BSA bureau (press release) - June 2nd, 2017
- IPS Cell Therapy - Page 5423 IPS Cell Therapy - May 31st, 2017
- Stem-cell therapy for cancer comes closer home - The New Indian Express - May 23rd, 2017
- Lab-grown blood stem cells - Nature Middle East - May 23rd, 2017
- Researchers Get Closer to First Lab-Grown Blood Stem Cells - Vital Updates - May 20th, 2017
- Approaching a decades-old goal: Making blood stem cells from patients' own cells - Science Daily - May 19th, 2017
- Cell potency - Wikipedia - May 17th, 2017
- Engineering human stem cells to model the kidney's filtration barrier on a chip - Science Daily - May 14th, 2017
- Pros and Cons of Stem Cell Therapy - Health Guidance - May 13th, 2017
- Hundreds of new stem cell lines ready to help research - The San Diego Union-Tribune - May 11th, 2017
- Researchers work to create kidney filtration barrier on a chip - Harvard Gazette - May 11th, 2017
- Shinya Yamanaka - Wikipedia - May 10th, 2017
- Engineering human stem cells to model the kidney's filtration barrier on a chip - Harvard School of Engineering and Applied Sciences - May 10th, 2017
- Stem Cell Glossary - May 8th, 2017
- Cellaria and Biological Industries USA Partner on Stem Cell Media ... - EconoTimes - May 5th, 2017
- Cellaria and Biological Industries USA Partner on Stem Cell Media ... - Yahoo Finance - May 4th, 2017
- CSU's use of fetal tissue for HIV/AIDS research sparks controversy - Rocky Mountain Collegian - May 4th, 2017
- Latest report on regenerative medicine market just published - WhaTech - May 4th, 2017
- World's 1st Stem Cell Transplant from Donor to Man's Eye Shows Promise of Restoring Sight - EnviroNews (registration) (blog) - April 27th, 2017
- Stem cell-based treatment prevents transplant rejection, in animal study - The San Diego Union-Tribune - April 23rd, 2017
- Cellular Dynamics International Signs Collaboration Agreement with Harvard Stem Cell Institute - Business Wire (press release) - April 20th, 2017
- Plasticell And Kings College London To Collaborate In Trials Of ... - Clinical Leader - April 20th, 2017
- Cellular Dynamics International Signs Distribution Deal with STEMCELL Technologies - Yahoo Finance - April 20th, 2017
- Telomerase reverse transcriptase - Wikipedia - April 16th, 2017
- Sumitomo Dainippon buys cell therapy processing tech from Hitachi - In-PharmaTechnologist.com - April 12th, 2017